N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.
about
Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in ratsTreatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells.Advances in the discovery of N-acylethanolamine acid amidase inhibitorsAntineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicityInitial insight into the function of the lysosomal 66.3 kDa protein from mouse by means of X-ray crystallographyPalmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacyAntiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the ratPalmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cellsEffects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamideCharacterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamideEffects of pH on the inhibition of fatty acid amidohydrolase by ibuprofenPalmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptideDesign and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compoundsAmino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in RatsThe pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.Functional role of cannabinoid receptors in urinary bladder.Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice.Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors.Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease.Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent mannerCannabinoid receptor 2 agonist attenuates pain related behavior in rats with chronic alcohol/high fat diet induced pancreatitisEndocannabinoids and immune regulation.Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages.Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats.Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems.The expanding field of cannabimimetic and related lipid mediators.Dietary non-esterified oleic Acid decreases the jejunal levels of anorectic N-acylethanolamines.Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647.Activity-Based Probe for N-Acylethanolamine Acid Amidase.Anti-Inflammatory, Antioxidant and Crystallographic Studies of N-Palmitoyl-ethanol Amine (PEA) Derivatives.Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.Evaluation of fatty acid amides in the carrageenan-induced paw edema model.Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).Inhibitory effects of traditional herbal formula pyungwi-san on inflammatory response in vitro and in vivoOral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.Optimized extraction of 2-arachidonyl glycerol and anandamide from aortic tissue and plasma for quantification by LC-MS/MS.Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation.Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.
P2860
Q21203937-702146B4-8720-4C60-B23A-7C491B2D9436Q24630453-D4DC610C-6B30-4D77-A5E1-111416B53E47Q26866274-5EB94A41-4BC5-4132-A77A-02D5F9CFB03FQ27305830-6DB95D99-DD9B-4468-B435-AB2CB8F237CCQ27657154-73427B7D-A3B8-47FA-B5EB-57766E323004Q28066248-7CB91F4C-1ABF-4A57-9304-E8F222D94FF4Q28344879-F749DBF8-DDC1-483B-BEBA-FCC63E78B4B3Q28345246-E0934769-381C-4EC9-B05F-794C05CF81FEQ28345762-422CDA42-D431-4592-8D0B-DBCE655233B4Q28363051-F7756D07-5F46-4977-9B14-1F160DF61CA1Q28366569-8CC7DCE0-BAC2-424C-8B9A-C31107AD4886Q28390536-C846DAA3-5008-44AC-B9A1-25A5A75FFE44Q28482428-74B6A554-1D29-41AC-AD0E-B53F73A5EC0EQ28548007-BDC18B59-6AD8-49B8-972A-6C3D05162612Q31122398-0AF1301E-BE6F-42B4-832F-C653EE99BAD8Q33884859-DD2E066B-18F0-4413-A503-EABC0EF4EA85Q34083248-C2C85D8B-C05D-49DF-A696-93508881894BQ34101852-57FF3965-F792-44F3-9FE2-E90D6DD31D91Q34261073-777D0B15-F435-44B3-8739-5F0C6DF300CBQ34422088-6DD32349-4C5C-46D8-8408-6626B66B5115Q34565750-6F75F247-68E5-4910-BC59-0E7C5F0A3255Q34607419-EF004FB7-EB6F-4EF5-8C1E-25155D54E2E0Q34715657-4F880042-339E-40D1-AA2E-8D5B19BF409CQ34772868-059309D4-0E6F-4288-9501-31F0AAD9705AQ35044663-0F673EE6-5016-47F6-94C9-AEB22E85749AQ35048658-44F75DF8-0929-4248-983E-F6F6485BEC51Q35193895-0483452C-A385-41EA-9E7B-99A4D5C15272Q36019444-C3ADFDDF-A877-4DDF-B7F8-5B0DBFA0DBCDQ36074423-78DECFC1-6CB3-4A58-A913-90EAADACF96AQ36343053-C594B8BE-6848-4EC6-ADD8-69780A422E7BQ36348374-E422DA2A-3ACA-4A43-8ED7-2B0A6AB22191Q36384547-2036253A-23B3-4D6D-BCFD-E5352EEA6CF5Q36533477-40365626-F790-46EB-8716-A673C76AAFD0Q36711577-0029CA21-272A-4D1F-B59D-907932B3AB39Q36775237-D78A677D-3EEF-40F6-87A8-D46ECBF01655Q36956403-93CAD870-B6BF-49D7-A25A-B6F638A7E32EQ36997712-9A233BA8-BCD2-4221-95F0-CE50DE666000Q37143569-A9B79F54-4DA1-4907-A912-00714E2DB9FAQ37162136-79733376-A1E0-459D-BA3D-1B68529DE8D7Q37469677-6B1EA032-1C77-4425-8204-CB50F37D7E2C
P2860
N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.
description
1996 nî lūn-bûn
@nan
1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
N-(2-hydroxyethyl)hexadecanami ...... dulating mast cell activation.
@ast
N-(2-hydroxyethyl)hexadecanami ...... dulating mast cell activation.
@en
type
label
N-(2-hydroxyethyl)hexadecanami ...... dulating mast cell activation.
@ast
N-(2-hydroxyethyl)hexadecanami ...... dulating mast cell activation.
@en
prefLabel
N-(2-hydroxyethyl)hexadecanami ...... dulating mast cell activation.
@ast
N-(2-hydroxyethyl)hexadecanami ...... dulating mast cell activation.
@en
P2093
P1476
N-(2-hydroxyethyl)hexadecanami ...... dulating mast cell activation.
@en
P2093
P304
P356
10.1016/0014-2999(96)00015-5
P407
P577
1996-04-01T00:00:00Z